- Short report
- Open Access
Hypomethylation of intron1 of α-synuclein gene does not correlate with Parkinson’s disease
Molecular Brainvolume 10, Article number: 6 (2017)
Deregulation of α-synuclein encoding gene (SNCA) is one of the important facets of Parkinson’s disease (PD) research. DNA methylation status of SNCA-intron1 has been shown to regulate the α-synuclein expression. The present study is aimed at investigating whether methylation of SNCA-intron1 is associated with higher expression of α-synuclein in PD. We have investigated the intron1 methylation status from 16 post-mortem brain samples comprised of 8 PD and 8 control subjects using bisulfite sequencing. We further correlated this methylation status with α-synuclein protein levels in substantia nigra of that individual using western blot analysis. We did not observe any significant difference in methylation of SNCA-intron1 region between PD and control samples. Moreover, no correlation was observed between methylation of SNCA-intron1 with α-synuclein level. Methylation of SNCA-intron1 region does not correlate with α-synuclein expression in PD samples.
Role of α-synuclein (α-SYN) in the pathogenesis of Parkinson′s disease (PD) is undeniable. Epigenetic regulation of α-SYN encoding gene (SNCA) has been greatly explored focusing on the methylation status of intron1 CpG island [1–9]. SNCA harbors 6 exons of which two upstream exons (1A and 1B) remain non-coding and part of its 5′ untranslated region . This intron1 region right before the first coding exon (exon 2) has been shown to regulate gene expression to a great extent by differential methylation of its CpG island and also by recruitment of several transcription factors [1, 10]. It is known that SNCA duplication/triplication is strongly associated with familial form of PD and this gene multiplication has also been shown to produce significantly higher mRNA in the cell [11–13]. Thus it can be conferred that higher expression of α-SYN can lead to PD pathogenesis. Since hypomethylation of CpGs of a gene-regulatory region is generally associated with increased expression of the gene, it is hypothesized that decrease in methylation in the intron1 of SNCA might increase expression of α-SYN in PD . In the present study, we have investigated the methylation status of the SNCA-intron1 in the substantia nigra of post-mortem PD patients and matched controls to decipher the association of DNA methylation in this region and PD pathogenesis. Moreover, we have also correlated this methylation status with the level of α-SYN in the subjects.
Post-mortem brain samples
In the present study, 16 post-mortem brain samples were investigated which consisted of 8 PD and 8 control subjects. The 7 samples from each group were obtained from NIH Neurobio bank consortium. Age ranged from 73 to 83 years (average 78.71 years) and post-mortem interval (PMI) varied from 6.7 hours to 15 hours (average 11.67 hours) in PD cases. Similarly, the age of the controls ranged from 54 years to 89 years with an average of 73.53 years. PMI for the controls varied from 10 hours to 30.25 hours (average 24.02 hours). One control and PD brain sample were procured from UK Brain bank. Age and post-mortem delay information for those two subjects were not available to us.
SNCA methylation analysis
Around 25 mg of SN tissue from each freshly frozen sample was precisely isolated by punch biopsy. DNA was extracted using Quick-DNA Universal Kit (Zymo Research; Catalogue No. D4068). Around 500 nanograms of DNA per sample was used for sodium bisulfite conversion using EZ DNA methylation kit (Zymo Research; Catalogue No. D5001) with little modifications following their optimization guide to ensure complete bisulfite conversion. Each reaction was made in duplicate to increase the amount of template DNA for the PCR. To amplify the intron1 region of SNCA spanning 23 CpG sites, we used the primers as described by Jowaed et al. . EpiMark Hot Start Taq DNA polymerase (NEB Inc; Catalogue No. M0490S) was used for the PCR amplification. The amplified PCR products of 444 base pair (Fig.1a) were then cloned into pGEM-T Easy vector (Promega; Catalogue No. A137A) and 9 to 10 positive colonies per PCR product were sequenced using T7 promoter or SP6 reverse primers.
Western blot analysis
Protein level of α-SYN from each sample was analyzed using 25-30 mg of freshly frozen SN tissue. Lysis was done in 100 μL of RIPA buffer (Radio Immuno Precipitation Assay buffer; 1% NP-40; 0.5% Sodium deoxycholate; 0.1% SDS, supplemented with protease inhibitor) at 4 °C. Equal amount of protein was loaded for all the samples in a 12% SDS-polyacrylamide gel and the separated proteins were then transferred onto a nitrocellulose membrane. The α-SYN and β-actin protein bands were detected using specific primary antibodies (α-SYN, BD Transduction Laboratories catalogue No. 610787, dilution 1: 500 and β-actin, Sigma, Catalogue No. A5316, dilution: 1:10,000). An anti-mouse HRP (Horse radish peroxidase)-conjugated secondary antibody (Jackson Immuno Research, dilution 1:5,000) was used to visualize the bands by enhanced chemiluminescent technique. Since, the two samples from UK brain bank were collected in 2011, there was not enough protein samples available at the time of study. Therefore, those two samples were not included for the studies on α-SYN protein level.
To calculate the relative level of methylation between PD and control subjects, QUMA software was used for the analysis with criteria that filters out the clonal PCR sequences and analyses only unique clones of the sample . To determine the amount of methylation for each individual at 23 different CpG sites, percentage methylation of each of the CpG site of those 9 to 10 clones were calculated and averaged. Non-parametric Mann-Whitney t-test was applied to assess the significant difference in the mean methylation level between control and PD. Difference in normalized α-SYN expression (α-SYN/β-actin) between the groups was measured using Mann-Whitney t-test. To determine the correlation between percentage-demethylation with α-SYN expression, non-parametric Spearman′s Rank correlation was used for the groups followed by linear regression analysis. All the statistical analyses and graphical representations were done using GraphPad Prism software version 5.0. Significance was assessed at 95% level. Data are presented as mean ± SEM.
In the present study, SNCA-intron1 region is comparably hypomethylated both in control (3.17 ± 0.66%) and PD (3.04 ± 0.81%) samples, and there is no significant difference in the methylation level between the groups (p = 0.9) (Fig.1b and c). We have also explored the mean methylation of individual CpG site (Fig. 1a and d). Pair-wise comparison of each CpG also did not reveal any significant difference in methylation between PD and control (Fig. 1d). The α-SYN protein level, although higher in PD cases, did not demonstrate any significant difference when compared to controls (p = 0.26) (Fig. 2a). At the same time, we did not observe any significant correlation between amount of unmethylated CpG and α-SYN expression in any group (r = -0.20, p = 0.67 control and r = 0.05, p = 0.92 PD) (Fig. 2b and c).
In the present cohort of samples, we did not find any significant correlation between either age (r = 0.39, p = 0.39 for controls; r = 0.10, p = 0.83 for PD) or PMI (r = -0.07, p = 0.89 for controls; r = 0.25, p = 0.59 for PD) of the study subjects with respective methylation status using Spearman′s rank correlation test. It was also previously shown by de Boni et al., that there is no correlation between PMI and methylation in Lewy Body disease (LBD) cases or in control . However, they found a slightly significant correlation with age of the LBD cases and methylation .
Regulation of SNCA expression by its methylation status of inton1 has been widely studied in relation to PD [1–9]. It′s important to note that SNCA like any other gene has several regulatory regions and variations, which have been shown to regulate this gene′s expression significantly irrespective of methylation status of SNCA-intron1 [15–17]. However, it’s also interesting that SNCA- intron1 methylation varies widely in different type of cells and demethylation of this region is positively correlated with higher expression of α-SYN [1, 2]. Therefore, it is important to study SNCA-intron1 methylation status in the SN of PD and control to understand if hypomethylation of this gene can be correlated with the disease.
In the present report, we have explored the methylation status of SNCA-intron1 in the SN of post-mortem PD and control subjects. As reported by others [1, 3, 6, 7], we also have observed that mean methylation of this locus in the SN is extremely low (Fig. 1c). We have studied a region of intron1 which was previously studied by Jowaed et al. , encompassing 23 CpG sites (Fig. 1a). We did not find any significant hypomethylation in PD subjects as compared to the controls (Fig. 1c). No association of SNCA-intron1 methylation in PD subjects was previously reported by other groups as well [3, 5, 7]. However, several groups reported significant difference in methylation between PD and control [1, 2, 4, 6, 8, 9]. This apparent difference in the outcome could be attributed to several factors like investigation of different CpGs regions in different studies, admixture of different cell types in the SN region apart from dopaminergic neurons and also may be due to difference in the sample characterization. Previously it was shown using luciferase reporter assay, that a significant demethylation of SNCA-intron1 could lead to an increase in α-SYN expression as compared to the completely methylated one . Similarly, HEK293 cells treated with dopamine demonstrated induction of a sizable amount of demethylation (94.4% to 21.2% methylation) in this region and increased α-SYN expression . Most of the studies on human brain samples including the present one have reported that SNCA-intron1 region in the SN is significantly hypomethylated (≥90%) both in control and PD which might be responsible for the constitutive expression of α-SYN in both groups. So, it can be envisaged that a small difference in methylation of SNCA-intron1 between PD and control, might have a limited effect on further expression of α-SYN . Since, methylation of individual CpG site also can play a role in transcription factor binding [1, 3, 6–8], we have examined all 23 CpG sites separately in both the groups but failed to find any significant difference (Fig. 1d). However, we observed that 2nd to 7th CpG sites have a trend of hypomethylation in PD (Fig. 1d). Two other groups found significant differences in some of the CpG sites in PD cases which they hypothesized to play a significant role in increased transcription of SNCA [1, 8]. On the other hand, another study couldn’t find any site-specific hypomethylation in intron1 when they studied different brain regions, instead they found hypermethylation of few CpGs in some tissues in specific stages of LBD (Table 1) . Some studies reported a difference in intron1 methylation between PD and controls from PBMC (peripheral blood mononuclear cells), however, some studies failed to find any such difference [5–8]. It has been already shown that methylation status varies between tissues and not necessarily mimics the situation in brain cell types [1, 2, 5–9].
Concurrently, we have also investigated α-SYN levels in these two groups but as expected, failed to find any significant difference in the protein level (Fig. 2a). However, both groups contained high as well as low α-SYN expressing subjects. This overall non-significant difference in protein levels between the groups might be partially explained by the observed non-significant difference in DNA methylation. One group showed a positive correlation between decreased intron1 methylation with increased α-SYN expression in PD cases . However, two other studies reported no difference in α-SYN expression between PD and controls but they found a significant hypomethylation in intron1 [8, 9]. This further points out a limited effect of intron1 methylation on overall α-SYN level or transcription.
Together, our study demonstrates a lack of association between SNCA-intron1 methylation and PD. However, this study points out the importance of studying a comprehensive epigenetic regulation of α-SYN rather than focusing only on DNA methylation status of this gene.
Human Embryonic Kidney 293T immortalized cell line
- SNCA :
Synuclein, Alpha (Non A4 Component Of Amyloid Precursor); Alpha-synuclein encoding gene
Jowaed A, et al. Methylation regulates alpha-synuclein expression and is decreased in Parkinson's disease patients' brains. J Neurosci. 2010;30:6355–9.
Matsumoto L, et al. CpG demethylation enhances alpha-synuclein expression and affects the pathogenesis of Parkinson's disease. PLoS One. 2010;5:e15522.
de Boni L, et al. Next-generation sequencing reveals regional differences of the alpha-synuclein methylation state independent of Lewy body disease. Neuromolecular Med. 2011;13:310–20.
Desplats P, et al. Alpha-synuclein sequesters Dnmt1 from the nucleus: a novel mechanism for epigenetic alterations in Lewy body diseases. J Biol Chem. 2011;286:9031–7.
Richter J, et al. No evidence for differential methylation of alpha-synuclein in leukocyte DNA of Parkinson's disease patients. Mov Disord. 2012;27:590–1.
Tan YY, et al. Methylation of alpha-synuclein and leucine-rich repeat kinase 2 in leukocyte DNA of Parkinson's disease patients. Parkinsonism Relat Disord. 2014;20:308–13.
Song Y, et al. Pyrosequencing analysis of SNCA methylation levels in leukocytes from Parkinson's disease patients. Neurosci Lett. 2014;569:85–8.
Ai SX, et al. Hypomethylation of SNCA in blood of patients with sporadic Parkinson's disease. J Neurol Sci. 2014;337:123–8.
Pihlstrom L, et al. Parkinson's disease correlates with promoter methylation in the alpha-synuclein gene. Mov Disord. 2015;30:577–80.
Scherzer CR, et al. GATA transcription factors directly regulate the Parkinson's disease-linked gene alpha-synuclein. Proc Natl Acad Sci U S A. 2008;105:10907–12.
Singleton AB, et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science. 2003;302:841.
Miller DW, et al. Alpha-synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication. Neurology. 2004;62:1835–8.
Chartier-Harlin MC, et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet. 2004;364:1167–9.
Kumaki Y, Oda M, Okano M. QUMA: quantification tool for methylation analysis. Nucleic Acids Res. 2008;36:W170–5.
Soldner F, et al. Parkinson-associated risk variant in distal enhancer of alpha-synuclein modulates target gene expression. Nature. 2016;533:95–9.
Rhinn H, et al. Alternative alpha-synuclein transcript usage as a convergent mechanism in Parkinson's disease pathology. Nat Commun. 2012;3:1084.
Chiba-Falek O, Nussbaum RL. Effect of allelic variation at the NACP-Rep1 repeat upstream of the alpha-synuclein gene (SNCA) on transcription in a cell culture luciferase reporter system. Hum Mol Genet. 2001;10:3101–9.
Author group gratefully acknowledge (i) Brain Endowment Bank of University of Miami, Miller School of Medicine; (ii) Human Brain and Spinal Fluid Resource Centre, UCLA, under NIH Neurobio bank, and (iii) Parkinson′s UK Brain Bank for their support in providing the human post-mortem brain samples.
The study is supported by the National Institute of Health (grant number 5R21NS088923-02) and Michael J Fox Foundation (Target Advancement) awarded to YSK. BE is recipient of UCF College of Medicine Honors in Major Scholarship and Distinguished Undergraduate Researcher Award. SB is recipient of University of Central Florida’s Graduate Dean's Dissertation Completion Fellowship.
Availability of data and materials
Please contact author for data requests.
Authors declare no competing interest.
SGT and YSK have conceptualized and organized the research project. SGT has executed the study. BE has helped in PCR product cloning. SB and SGT have performed the western blot analysis. Statistical analysis was designed and executed by SG and SGT. YSK has reviewed the analysis. Manuscript is written by SGT and it was reviewed and critiqued by all the authors. All authors read and approved the final manuscript.
Consent for publication
Ethics approval and consent to participate